N/A
Manufactured by Cipla USA Inc.
3,364 FDA adverse event reports analyzed
Last updated: 2026-04-15
ALFUZOSIN HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Cipla USA Inc.. The most commonly reported adverse reactions for ALFUZOSIN HYDROCHLORIDE include DRUG INEFFECTIVE, OFF LABEL USE, DYSPNOEA, DRUG INTERACTION, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALFUZOSIN HYDROCHLORIDE.
Out of 2,217 classified reports for ALFUZOSIN HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 3,364 FDA FAERS reports that mention ALFUZOSIN HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, DYSPNOEA, DRUG INTERACTION, FATIGUE, ACUTE KIDNEY INJURY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Cipla USA Inc. in connection with ALFUZOSIN HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.